세부전공

악성질환, 만성간질환, 간질환 합병증

질환군

간세포암종, 바이러스성 간염 (B형간염,C형간염), 간경화

증상군

체중감소, 황달, 복통, 피로감, 간수치 상승, 복부팽만, 혼수, 전신 부종, 위장관 출혈

김지훈 교수의 진료시간표

김지훈 교수의 상세정보

•  ~  1997 .02  :  고려대학교의과대학 의학과 학사
•  ~  2005 .08  :  고려대학교의과대학 대학원 석사
•  ~  2008 .02  :  고려대학교의과대학 대학원 박사

• 2005 .05  ~  2006 .02  :  고려대학교 구로병원 소화기내과 임상 강사
• 2005 .03  ~  2008 .02  :  국립암센터 간암센터 임상강사
• 2005 .03  ~  2008 .02  :  고려대학교 구로병원 소화기내과 임상 조교수
• 2008 .03  ~  2011 .02  :  고려대학교 구로병원 소화기내과 조교수
• 2011 .08  ~  2013 .02  :  Visiting Associate Professor, Systems Biology, MD Anderson Cancer Center, Houston, Texas, USA.
• 2011 .03  ~   :  고려대학교 구로병원 소화기내과 부교수

• 2013 .03  ~  2013 .12  :  대한간암학회-국립암센터, 간암 치료 가이드라인 제정 위원
• 2014 .03  ~  2015 .12  :  대한 간학회, B형 간염 가이드라인 제정 위원
• 2013 .12  ~  2015 .12  :  대한 간학회, 간행 위원
• 2013 .12  ~  2015 .12  :  대한 소화기학회, 편집 위원
• 2014 .06  ~  2015 .06  :  대한 간암학회, 보험위원장
• 2014 .06  ~  2016 .06  :  대한 간암학회, 학술위원
• 2015 .10  ~   :  대한간학회, 재무이사

• 2010 .01  ~  2011 .12  :  질병관리본부, B형 간염 전문분과 위원
• 2013 .06  ~   :  심사평가원, 약제급여평가 위원
• 2013 .03  ~  2016 .05  :  의료분쟁조정원, 비상임 심의 위원
• 2013 .03  ~   :  남부지방검찰청, 형집행정지 심의 위원
• 2015 .08  ~   :  심사평가원, 진료심사평가위원

• [SCI] (Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies)
• [SCI] (Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma)
• [SCI] (Um SH BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A)
• [SCI] (The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?)
• [SCI] (Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma)
• [SCI] (Risk Factors for Developing Hyponatremia During Terlipressin Treatment: A Retrospective Analyses in Variceal Bleeding)
• [SCI] (Risk Factors for Developing Hyponatremia During Terlipressin Treatment: A Retrospective Analyses in Variceal Bleeding)
• [SCI] (Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma)
• [SCI] (Pancreatic mucinous cystadenoma of borderline malignancy associated with Clonorchis sinensis)
• [SCI] (The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels inPatients without Hepatocellular Carcinoma)
• [SCI] (Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data)
• [SCI] (Butein effects in colitis and interleukin-6/signal transducer and activator of transcription 3 expression)
• [SCI] (Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years)
• [SCI] (Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?)
• [SCI] (Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation)
• [SCI] (Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Adefovir Therapy for Adefovir-resistant Chronic Hepatitis B)
• [SCI] (Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line)
• [SCI] (2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity)
• [SCI] (Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability)
• [SCI] (Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma)
• [SCI] (Is propofol safe when administered to cirrhotic patients during sedative endoscopy?)
• [SCI] (Clinical implications of the titer of serum hepatitis B surface antigen during the natural history of hepatitis B virus infection)

최종수정일 : 2019.02.28